# Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

> **NCT01371604** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 68 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** IDX184
- **BIOLOGICAL:** Peginterferon alfa-2a (Peg-IFN)
- **DRUG:** Ribavirin (RBV)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01371604
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-03
- **Final completion:** 2014-10
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2015-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371604, "Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01371604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*